Frequency of restrictive pulmonary function tests in patients with chronic Hepatitis C
Keywords:Liver Cirrhosis, Pulmonary fibrosis, Respiratory Function Tests, Hepatitis C
Hepatis C infection is a common health problem world wide and is the major cause of chronic liver disease in Pakistan. Common complications of chronic hepatitis c infection are cirrhosis, ascities and hepatocellular carcinoma. Also HCV infection is associated with several extra hepatic manifestations including interstitial lung fibrosis. It has been found that frequency of pulmonary fibrosis is increased in patients with cirrhosis of liver as the stage of cirrhosis advances.This lung fibrosis can cause restrictive pattern of pulmonary function tests. This study was conducted to determine frequency of restrictive pulmonary function in patients with different stages of chronic hepatitis C infection, based on child pough classification.
This is descriptive case study
99 patients of age range 20 to 80 year, both males and females having chronic hepatitis C infection and interferon based treatment naïve patients were included from outpatient and inpatient department were selected. Patients were divided into three groups according to child’s criteria i.e. group A, group B, and group C. Pulmonary function tests were performed on patients in all three groups to look for FEV1/FVC ratio in all patients. FEV1/FVC ratio more than 80 was considered as restrictive pulmonary function.
Out of 99 patients 32(35%) were found to have restrictive pattern of pulmonary functions
Chronic hepatitis C infection is associated with restrictive pattern of pulmonary function, suggestive of pulmonary fibrosis.
Nadeem MA, Waseem T, Sheikh AM, Grumman N, Irfan K, Hasnain SS. Hepatitis C virus: an alarmingly increasing cause of liver cirrhosis in Pakistan. Pak J Gastroenterol. 2002;16(1):3–8.
Hamid S, Masood M. Frequency of pulmonary fibrosis in patients with cirrhosis of liver. Esculapio. 2008;4(1):21–3.
Anstee Q, Jones D. Hepatology. Davidson’s principles and practice of medicine. 23rd ed. London: Elsevier; 2018. 877–8 p.
Lawrence S, Friedman M. Liver biliary tract and pancreas. In: Current medical diagnosis and treatment. Newyork: McGraw Hill; 2019. p. 697–8.
Demir C, Demir M. Effect of hepatitis C virus infection on the right ventricular functions, pulmonary arterypressure and pulmonary vascular resistance. Int J Clin Exp Med. 2014;7(8):2314.
Zidan M, Daabis R, El Sayed P, Samir S. Prevalence of chronic hepatitis C virus (HCV) infection in patients with idiopathic pulmonary fibrosis. Egypt J Chest Dis Tuberc. 2015;64(4):907–13.
Elhelaly S, Ragab M, Elkomy H, Fathy T. Pulmonary hazards of chronic hepatitis C virus infection treatment with Pegylated interferon and ribavirin vs. untreated patients. Egypt J
Chest Dis Tuberc. 2013;62(2):325–9.
Franciscus A. An overview of extrahepatic manifestations of hepatitis C. HCSP Fact Sheet. 2015;7:1–6.
Viegi G, Fornai E, Ferri C, Di Munno O, Begliomini E, Vitali C, et al. Lung function in essential mixed cryoglobulinemia: a short-term follow-up. Clin Rheumatol. 1989;8(3):331–8.
Weidensaul D, Imam T, Holyst M, King PD, Mcmurray RW. Polymyositis, pulmonary fibrosis, and hepatitis C. Arthritis Rheum. 1995;38(3):437–9.
Masood M, Hamid S. Association of progression of pulmonary fibrosis in cirrhosis. Esculapio. 2011;7(1):12–4.
Ohta K, Ueda T, Nagai S, Yamada K, Yamaguchi M, Nakano J, et al. Pathogenesis of idiopathic pulmonary fibrosis–is hepatitis C virus involved? Nihon Kyobu Shikkan Gakkai Zasshi. 1993;31:32–5.
Irving WL, Day S, Johnston I. Virus Infertion. Am Rev Respir Dis. 1993;148:1683–4.
Meliconi R, Andreone P, Fasano L, Galli S, Pacilli A, Miniero R, et al. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax. 1996;51(3):315–7.
Ferri C, La Civita L, Fazzi P, Solfanelli S, Lombardini F, Begliomini E, et al. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol. 1997;36(3):360–5.
Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol WJG. 2008;14(38):5880.
Abbas R, Massoud K, Hegazy AM, Shehata M. Risk of Pulmonary Fibrosis in Egyptian Patients with Chronic Hepatitis-C-Infection. Int J Intern Med. 2015;4(1):1–8.
Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25(3):283–91.
Karino Y, Hige S, Matsushima T, Toyota J. Interstitial pneumonia induced by interferon therapy in type C hepatitis. Nihon Rinsho. 1994;52(7):1905–9.20.
Bombardieri S, Paoletti P, Ferri C, Di Munno O, Fornai E, Giuntini C. Lung involvement in essential mixed cryoglobulinemia. Am J Med. 1979;66(5):748–56.
How to Cite
Copyright (c) 2021 shahid Hamid, Khalid, fawad, Asia Firdous
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Under CC-BY Liscence, you are free to
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- for any purpose, even commercially.
Please cite the author everytime you share. Thank You